絞り込み

16766

広告

[Endovascular treatment for carotid artery stenosis].

著者 Gensicke H , Engelter S , Bonati L
Ther Umsch.2012 Sep ; 69(9):523-35.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Neurologie, Stroke Unit, Universitätsspital Basel.

スターを付ける スターを付ける     (32view , 0users)

Full Text Sources

About 10 - 15 % of all ischaemic strokes are caused by focal atherosclerosis and consecutive narrowing (stenosis) of the internal carotid artery (ICA). Carotid endarterectomy (CEA) - the standard treatment for carotid stenosis - substantially reduces the risk of recurrent stroke among patients who have had ischaemic symptoms such as stroke or transient ischaemic attack attributable to the stenosis. To a smaller extent, CEA also reduces the risk of first stroke in patients with hitherto asymptomatic carotid stenosis. Endovascular treatment techniques, including balloon angioplasty in the initial years and more recently, carotid artery stenting (CAS), have been developed as an alternative to CEA for treating carotid stenosis without necessating surgery. The present review compares risks and benefits between CAS and CEA summarising the existing evidence derived from randomised controlled trials. Among patients with symptomatic carotid stenosis, CEA is associated with a lower risk of peri-procedural stroke or death than CAS. CAS reduces the risk of peri-procedural myocardial infarction, cranial nerve palsy and access site haematoma compared with CEA. The excess peri-procedural stroke risk associated with CAS appears to be limited to patients older than 70 years while in younger patients, CAS is as safe as CEA. Both treatments are equally effective in preventing recurrent stroke in the first few years following treatment. However, recurrent stenosis appears to be more common after CAS, and longer-term follow-up of ongoing trials should be awaited to investigate whether restenosis might be associated with recurrent stroke. The best treatment approach for patients with asymptomatic carotid stenosis remains to be determined in ongoing clinical trials.
PMID: 22923356 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード